摘要
弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是我国常见的成人非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)之一,随着以利妥昔单抗为基础的联合化疗方案的应用,使患者的缓解率及生存期有了明显的改善,但对于复发/难治性DLBCL患者而言则获益不佳,且预后较差。近些年,应用嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immunotherapy,CAR-T)治疗淋巴瘤,改善了淋巴瘤患者的生存状况,为CAR-T治疗复发/难治性DLBCL奠定基础。文章就CAR-T疗法在复发/难治性DLBCL中的研究进展进行概述。
Diffuse large B-cell lymphoma(DLBCL)is one of the common adult non-Hodgkin lymphoma(NHL)in China.With the application of rituximab-based combination chemotherapy regimen,the patient's remission rate and survival time have been significantly improved.But for patients with relapsed/refractory DLBCL,it has poor benefit and poor prognosis.In recent years,the application of chimeric antigen receptor T-cell immunotherapy(CAR-T)in the treatment of lymphoma has improved the survival status of lymphoma patients and laid the foundation for CAR-T treatment of relapsed/refractory DLBCL.This review summarizes the research progress of CAR-T therapy in relapsed/refractory DLBCL.
作者
马晔
葛晓燕
Ma Ye;Ge Xiaoyan(Department of Hematology,Second Hospital of Shanxi Medical University,Taiyuan 030000,China)
出处
《国际免疫学杂志》
CAS
2022年第5期537-542,共6页
International Journal of Immunology
